Market Place
Sourcing Support
Galera Announces Board Approval of Complete Liquidation and Dissolution
14 Aug 2024 //
GLOBENEWSWIRE
Galera Bids Farewell, Initiates Wind-Down With Layoffs
14 Aug 2024 //
FIERCE BIOTECH
Galera Reports First Quarter 2024 Financial Results and Recent Corporate Updates
13 May 2024 //
GLOBENEWSWIRE
Galera Adopts Limited Duration Stockholder Rights Agreement
03 May 2024 //
GLOBENEWSWIRE
Galera Reports Fourth Quarter and Full Year 2023 Financial Results
28 Mar 2024 //
GLOBENEWSWIRE
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
14 Nov 2023 //
GLOBENEWSWIRE
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
31 Oct 2023 //
GLOBENEWSWIRE
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
18 Sep 2023 //
GLOBENEWSWIRE
Galera to Participate in the H.C. Wainwright 25th Annual Global Conference
05 Sep 2023 //
GLOBENEWSWIRE
Galera Reports Second Quarter 2023 Financial Results & Recent Corporate Updates
14 Aug 2023 //
GLOBENEWSWIRE
Galera tanks after FDA declines to approve avasopasem for patients with cancer
10 Aug 2023 //
REUTERS
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial
05 Jun 2023 //
GLOBENEWSWIRE
Galera earns key FDA designation for pancreatic cancer drug
19 May 2023 //
CLINICAL TRIALS ARENA
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem
18 May 2023 //
GLOBENEWSWIRE
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
11 May 2023 //
GLOBENEWSWIRE
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 May 2023 //
GLOBENEWSWIRE
Galera Expands Commercial Leadership Team
01 May 2023 //
CONTRACT PHARMA
Galera to Present 1Y Reductions in Cisplatin-Related Chronic Kidney Disease Data
26 Apr 2023 //
GLOBENEWSWIRE
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial
10 Mar 2023 //
GLOBENEWSWIRE
Galera Reports Fourth Quarter and Full Year 2022 Financial Results
08 Mar 2023 //
GLOBENEWSWIRE
Galera Announces Priority Review of Avasopasem NDA for Oral Mucositis
15 Feb 2023 //
GLOBENEWSWIRE
Galera Announces Pricing of Direct Offering of $30M of Common Stock
15 Feb 2023 //
GLOBENEWSWIRE
FDA to review Galera’s drug for radiotherapy complication immediately seeks $30M
15 Feb 2023 //
ENDPTS
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
12 Dec 2022 //
GLOBENEWSWIRE
Galera to Present at Piper Sandler Annual Healthcare Conference
22 Nov 2022 //
GLOBENEWSWIRE
Galera Announces Presentation of Phase 3 ROMAN Data at 2022 ASTRO Meeting
26 Oct 2022 //
GLOBENEWSWIRE
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO)
26 Sep 2022 //
GLOBENEWSWIRE
Galera to Participate in the H.C. Wainwright 24th AnnualGIC
06 Sep 2022 //
GLOBENEWSWIRE
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
01 Sep 2022 //
GLOBENEWSWIRE
Galera Reports Second Quarter 2022 Financial Results
09 Aug 2022 //
GLOBENEWSWIRE
Galera Announces Results from PI Stage of GRECO-1 Trial of Rucosopasem
29 Jun 2022 //
GLOBENEWSWIRE
Galera to Present at Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Galera`s Oral Presentation at 2022 ASCO on PIII ROMAN Trial of Avasopasem
26 May 2022 //
GLOBENEWSWIRE
Galera Announces Plan to Submit Avasopasem NDA by Year End
16 May 2022 //
GLOBENEWSWIRE
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
16 May 2022 //
GLOBENEWSWIRE
Galera to Present at 2022 ASCO Annual Meeting
27 Apr 2022 //
GLOBENEWSWIRE
Tiziana says Positive Data from Secondary Progressive MS Study of Foralumab
10 Mar 2022 //
GLOBENEWSWIRE
Galera shares rise over 100% as phase 3 flop deemed an error
15 Dec 2021 //
FIERCEBIOTECH
Galera Announces Primary Endpoint Met Statistical Significance in Topline
14 Dec 2021 //
GLOBENEWSWIRE
Galera shares slide as radiotherapy complication drug fails
20 Oct 2021 //
FIERCEBIOTECH
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy
19 Oct 2021 //
GLOBENEWSWIRE
Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced (SOM)
14 Sep 2021 //
GLOBENEWSWIRE
Galera Announces Data from Pancreatic Cancer Trial Showing Efficacy enhancement
08 Sep 2021 //
GLOBENEWSWIRE
Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments
10 Aug 2021 //
GLOBENEWSWIRE
Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments
10 Aug 2021 //
GLOBENEWSWIRE
Galera Announces Completion of Enrollment in Phase 3 Trial of Avasopasem
28 Jun 2021 //
GLOBENEWSWIRE
Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2
17 May 2021 //
GLOBENEWSWIRE
Galera claims positive update in pancreatic cancer but doesn`t report p-values
29 Apr 2021 //
ENDPTS
Galera Announces Updated Data from its Randomized, Multicenter
28 Apr 2021 //
GLOBENEWSWIRE
Galera Announces Interim Data from Pilot Phase 1/2 Trial of GC4419
27 Oct 2020 //
GLOBENEWSWIRE
Galera Announces Positive Interim Data from First Cohort Ph 1/2 Trial of GC4419
23 Oct 2020 //
GLOBENEWSWIRE
Galera Announces Dosing of First Patient in the Ph1/2 GRECO-1 Trial of GC4711
22 Oct 2020 //
GLOBENEWSWIRE
Galera Therapeutics Announces beginning of Clinical Trial of GC4419 for COVID-19
16 Sep 2020 //
BIOSPACE
Galera Therapeutics Announces Avasopasem Manganese Improved Cisplatin
29 May 2020 //
GLOBENEWSWIRE
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced ckd
18 May 2020 //
GLOBENEWSWIRE
Galera Therapeutics Announces New Data from the Phase 2b Trial
13 May 2020 //
GLOBENEWSWIRE
Galera`s Announces Presentation of Avasopasem Manganese Data at ASCO 2020
30 Apr 2020 //
GLOBENEWSWIRE
Galera`s Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit
27 Feb 2020 //
GLOBENEWSWIRE
Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419)
24 Feb 2020 //
YAHOO
Galera Therapeutics Announces Publication of GC4419 Data
05 Dec 2019 //
GLOBE NEWSWIRE
